Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Perc FDA Decision: Tarsus Pharmaceuticals, Inc. (TARS)

The Phase 4 date for Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Perc by Tarsus Pharmaceuticals, Inc. (TARS) is scheduled for October 1, 2029. This is the target date for the FDA to make a decision on this application.

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Perc is being developed by Tarsus Pharmaceuticals, Inc. for the treatment of its target indication. It is currently in Phase 4 clinical trials.

If Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Perc receives FDA approval, Tarsus Pharmaceuticals, Inc. (TARS) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 4 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for TARS on DilutionWatch at dilutionwatch.com/stock/TARS.html.

You can view the full BiotechSigns company profile for Tarsus Pharmaceuticals, Inc. (TARS) at biotechsign.com/app/company/TARS, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.